Contact the Breast and Gynecologic Cancer Research Group

Phone: 240-276-7051

Fax: 240-276-7828

For Regular Mail

Breast and Gynecologic Cancer Research Group, DCP

9609 Medical Center Drive
MSC 9783
Bethesda, MD 20892-9783
United States

For Courier Packages

Breast and Gynecologic Cancer Research Group, DCP

9609 Medical Center Drive
Rockville, MD 20850
United States

Funding Opportunities

Title	Announcement Number	Activity Code	Clinical Trials Status	Expiration Date Sort descending	Program Official
NCI Clinical and Translational Exploratory/Developmental Studies	PAR-25-139 (R21 Clinical Trial Optional)	R21	Clinical Trial Optional	07/02/2025	Marjorie Perloff, M.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics	PAR-23-279 (R01 Clinical Trial Optional)	R01	Clinical Trial Optional	01/08/2027	Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics	PAR-25-069 (R01 Clinical Trial Optional)	R01	Clinical Trial Optional	01/08/2027	Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics	PAR-23-280 (R21 Clinical Trial Not Allowed)	R21	Clinical Trial Not Allowed	01/08/2027	Edward Sauter, M.D., Ph.D.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis	PAR-24-085 (R01 Clinical Trial Required)	R01	Clinical Trial Required	01/08/2027	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics	PAR-25-070 (R21 Clinical Trial Not Allowed)	R21	Clinical Trial Not Allowed	01/08/2027	Edward Sauter, M.D., Ph.D.
Notice of Special Interest (NOSI): Factors impacting how Time-Restricted Eating (TRE) influences cancer-related outcomes	NOT-CA-24-073			05/08/2027	Edward Sauter, M.D., Ph.D.
Cancer Prevention and Control Clinical Trials Planning Grant Program	PAR-25-104 (R34 Clinical Trials Optional)	R34		10/26/2027	Goli Samimi, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Planning Grant Program	PAR-25-103 (U34 Clinical Trials Optional)	U34		10/26/2027	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies	PAR-25-145 (R01 Clinical Trial Optional)	R01	Clinical Trial Optional	01/08/2028	Rachel Altshuler, Ph.D.